Psychiatry and
Behavioral Sciences

Valproate In Dementia (The VALID Study)

Contact: Emily Gere (650) 849-0339

[This study is no longer recruiting subjects.]

Valproate is an FDA approved anticonvulsant medication which may be helpful in slowing cognitive decline in Alzheimer’s disease and other related symptoms. The VALID Study is a nationwide clinical research study to evaluate whether Valproate is effective in delaying, weakening or preventing difficult behaviors in individuals with Alzheimer’s disease. Researchers will also examine whether Valproate has an effect on slowing the progression of Alzheimer’s disease overall. VALID is sponsored by the Alzheimer’s Disease Cooperative Study and funded by the National Institute on Aging (NIA). Participants in this study will be assigned at random to receive Valproate or placebo (inactive pill) for 26 months. Throughout the study, participants will be assessed regularly by physicians and other qualified health care professionals. For additional information regarding this research study, please contact Emily Gere at (650) 849-0339.

 

Stanford Medicine Resources:

Footer Links: